Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment